Completed PHASE1 INTERVENTIONAL 2-arm NCT00876161

DAS181 Single Dose Escalation Study in Healthy Adults

Phase 1 Clinical Study With DAS181: Double-Blind, Randomized, Placebo-Controlled, Single Dose Escalation Study in Healthy Adults

Sponsor: Ansun Biopharma, Inc.

Conditions Healthy

Interventions DAS181 Lactose

Updated 7 times since 2017 Last updated: Aug 1, 2019 Started: May 18, 2009 Primary completion: Dec 31, 2009 Completion: May 23, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00876161, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Ansun Biopharma, Inc., it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Sep 2019 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Ansun Biopharma, Inc.
National Institute of Allergy and Infectious Diseases (NIAID)

Data source: Ansun Biopharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Overland Park, United States